Clinical Trials Logo

Chemotherapeutic Toxicity clinical trials

View clinical trials related to Chemotherapeutic Toxicity.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04607668 Terminated - Clinical trials for Colorectal Cancer Metastatic

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

PRESERVE1
Start date: October 16, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in patients with pMMR/MSS mCRC who have not received systemic therapy for metastatic disease.